PI3K inhibitor

DRUG CLASS:

PI3K inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation	Colorectal Cancer	PIK3CA mutation + KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval Oncogene - 3 weeks (New C3) alpelisib Sensitive : A1 Oncogene - 3wk	alpelisib Sensitive: A1 - Approval Oncogene - 3 weeks alpelisib Sensitive : A1 Oncogene - 3 weeks - (New C3)
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline CDK6 inhibitor + alpelisib Sensitive : A2	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline CDK6 inhibitor + alpelisib Sensitive : A2
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline CDK4 inhibitor + alpelisib Sensitive : A2	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline CDK4 inhibitor + alpelisib Sensitive : A2
PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PI3K inhibitor Sensitive: B - Late Trials PI3K inhibitor Sensitive : B	PI3K inhibitor Sensitive: B - Late Trials PI3K inhibitor Sensitive : B
AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials chidamide Sensitive : B	chidamide Sensitive: B - Late Trials chidamide Sensitive : B
PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA H1047X	HER2 Negative Breast Cancer	PIK3CA H1047X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA E545X	HER2 Negative Breast Cancer	PIK3CA E545X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN negative	Prostate Cancer	PTEN negative	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA N345K + PIK3CA N1044K	Breast Cancer	PIK3CA N345K + PIK3CA N1044K	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA G106_108del	Breast Cancer	PIK3CA G106_108del	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA R38C	Breast Cancer	PIK3CA R38C	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA Q75E	Breast Cancer	PIK3CA Q75E	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA N345K	Breast Cancer	PIK3CA N345K	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B
PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1

PI3K inhibitor

PI3K inhibitor

Associations(331)

Associations
(331)